Much of psilocybin’s best-characterized pharmacology begins with one receptor. Its active form, psilocin, acts mainly as an agonist at the serotonin 5-HT2A receptor — switching the receptor on the way serotonin would — with a secondary role at 5-HT1A and other serotonin sites. This is not a loose association: in humans, blocking 5-HT2A with the drug ketanserin abolishes psilocybin’s psychedelic effects, and the strength of the experience scales with how much of the receptor population is occupied. That makes 5-HT2A the best-established fact in the whole field. The catch for microdosing is that this evidence was gathered at perceptual doses; how much a sub-perceptual dose engages the same receptor, and whether that is enough to matter, has not been measured in people.
The receptor at the centre of everything
Classic psychedelics — psilocybin, LSD, mescaline, DMT — are chemically diverse, but they converge on a single mechanism: agonism at the serotonin 5-HT2A receptor. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 An agonist is a molecule that binds a receptor and activates it, producing the kind of downstream signal the receptor’s natural messenger would. For psilocybin, the active agonist is not the molecule you swallow but its metabolite, psilocin, which acts as an agonist — and at some sites a partial agonist — at 5-HT2A. [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 The conversion of psilocybin to psilocin, and the kinetics that follow, are covered in the pharmacokinetics article; here the focus is what happens once psilocin reaches the receptor.
5-HT2A receptors are widely distributed in the cortex, with high density in the prefrontal cortex — the region most associated with planning, mood regulation, and self-referential thought. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 They are important not only for their density but for where they are expressed, across cortical networks involved in perception, cognition, and the integration of information. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 This anatomical fact is part of why the receptor is interesting for mood and cognition: the same receptor system is implicated in the action of several psychiatric medications, though those drugs engage it in different ways and directions. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
The evidence that 5-HT2A is causal, not just correlated
It is one thing to observe that psychedelics bind 5-HT2A; it is another to show that this binding is responsible for their effects. The field has unusually direct evidence on this point, of a kind much of microdosing research lacks.
The decisive experiment is a receptor-blocking study. When healthy volunteers were pretreated with ketanserin — a selective 5-HT2A antagonist that occupies the receptor without activating it — the psychedelic effects of a subsequent dose of psilocybin were suppressed in a dose-dependent manner. [3] Peer-reviewed Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action doi:10.1097/00001756-199812010-00024 Blocking the receptor substantially suppresses the characteristic psychedelic effect — and that is the logic of a causal test: if blocking one specific receptor largely removes the response, that receptor is doing the central work, and the result cannot be explained by some other pathway. [3] Peer-reviewed Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action doi:10.1097/00001756-199812010-00024
A second, complementary line of evidence comes from human brain imaging. Using positron emission tomography, researchers measured how much of the brain’s 5-HT2A receptor population was occupied after psilocybin and found that the intensity of the subjective experience tracked both that occupancy and the concentration of psilocin in the blood. [4] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9 The dose-effect relationship, in other words, runs through the receptor. A related study found that a single psilocybin dose was associated with long-term increases in mindfulness, with the size of that change related proportionally to neocortical 5-HT2A receptor binding — tentatively tying the receptor to lasting psychological outcomes, again at perceptual doses. [5] Peer-reviewed A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding doi:10.1016/j.euroneuro.2020.02.001
Receptor activation is a gradient
It is tempting to read the causal evidence as a switch: psilocin engages 5-HT2A, therefore the effect follows. Receptors do not work that way. Activation exists across a range — different levels of receptor engagement produce different downstream effects — which is exactly what the occupancy imaging shows, with the experience scaling with how much of the receptor population is occupied rather than flipping on at a single point. [4] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9 A full psychedelic dose and a sub-perceptual dose can involve the same receptor system while producing very different biological and psychological outcomes.
This reframes the microdosing question precisely. The unresolved issue is not whether psilocin can activate 5-HT2A receptors — it plainly can — but whether the degree and pattern of activation below the perceptual threshold are sufficient to create measurable, durable changes. [6] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 “Same receptor” is not the same claim as “same effect,” and the human data that would locate a microdose on this gradient do not yet exist.
What happens downstream of the receptor
Activating 5-HT2A does not produce an effect by itself; it initiates a cascade of intracellular signalling. The receptor is coupled to signalling pathways that, among other things, increase cortical excitability and engage the molecular machinery associated with neural plasticity — including pathways linked to neurotrophic signalling. [7] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 In preclinical models, this is the bridge between a receptor event and a structural change in neurons, and it is treated in detail in the neuroplasticity and BDNF article. [7] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 The relevant point for this article is that 5-HT2A agonism is the entry point: the receptor is where the drug acts, and everything attributed to psilocybin downstream depends on this first step.
Modern receptor biology adds a further layer: activating a receptor does not always produce one identical response. Different agonists can stabilize the same receptor in different conformations that favour different downstream signalling pathways — a phenomenon known as functional selectivity, or biased agonism. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 For psychedelics this matters because it means “5-HT2A agonist” is not a single, uniform action; which downstream pathways a given compound preferentially engages can differ, and this is an active area of pharmacology relevant to how receptor activation translates into plasticity and behaviour. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
5-HT1A and the rest of the receptor profile
5-HT2A is primary, but it is not the whole story. Psilocin also interacts with other serotonin receptors, notably 5-HT1A, and the balance of activity across these sites shapes the overall response. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 5-HT1A activation is thought to modulate, and in some respects dampen, aspects of the 5-HT2A-driven response, which is one reason the subjective effect is not a simple linear function of 5-HT2A occupancy alone. For the purposes of understanding microdosing, the receptor profile matters because it cautions against treating “5-HT2A agonism” as a single dial: the real system is a mixture of effects at several related receptors, and the net result depends on the relative engagement of each.
| Claim | Evidence | Dose range tested |
|---|---|---|
| Psilocin is a 5-HT2A agonist | Receptor pharmacology, well characterized | In vitro and in vivo |
| 5-HT2A activation is necessary for the psychedelic effect | Ketanserin blockade in humans | Perceptual doses |
| Experience intensity tracks 5-HT2A occupancy | Human PET imaging | Perceptual doses (3–30 mg) |
| Psilocin also engages 5-HT1A and other sites | Receptor-binding studies | In vitro |
| Sub-perceptual doses engage 5-HT2A enough to matter | Not directly measured | Microdose — untested |
The microdose gap
Every causal and quantitative result above shares a feature: it was obtained at doses large enough to produce a noticeable experience. The ketanserin study blocked a psychedelic dose; the occupancy imaging used doses in the 3–30 mg range, which span the threshold of clear subjective effects. [3] Peer-reviewed Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action doi:10.1097/00001756-199812010-00024 [4] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9 A microdose, by definition, sits below that threshold and therefore occupies far fewer receptors.
This is where the strength of the mechanism stops translating cleanly. We do not have human occupancy data at sub-perceptual doses, so the degree of 5-HT2A engagement a microdose produces is essentially uncharacterized, and whether that smaller signal is sufficient to drive any lasting change is unknown. [6] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 The receptor pharmacology tells us the pathway a microdose would use; it does not tell us that the pathway is engaged strongly enough, at sub-perceptual doses, to produce a reliable effect — and the controlled studies that test the practice directly have not established one beyond expectation. [8] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
Receptor regulation and the SSRI question
A practical question that follows from the receptor mechanism concerns antidepressants. Long-term exposure to selective serotonin reuptake inhibitors (SSRIs) has been associated with adaptive changes in serotonin signalling, including changes in 5-HT2A receptor expression and sensitivity. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 Because psilocin produces its effects by activating those receptors, a system adapted in this way would be expected to respond more weakly. That receptor-level reasoning is the most likely explanation for the commonly reported observation that long-term SSRI users notice a blunted or absent response, though the degree varies between medications and individuals. This is a statement about pharmacology, not a safety claim and not advice: how psilocybin interacts with specific medications in practice is a clinical question, and medication changes belong with a prescribing clinician. The broader topic is handled in the Interactions cluster.
Receptor adaptation is a general property of the system, not unique to SSRIs. Serotonin receptors are dynamic: repeated stimulation can lead to compensatory changes in receptor availability or sensitivity. This is the same kind of regulation that underlies tolerance to repeated dosing, and it is one reason dosing schedules — rather than continuous exposure — feature in how the practice is structured, a topic taken up in the Protocols cluster.
- Agonist
- A molecule that binds a receptor and switches it on; psilocin is an agonist at 5-HT2A, activating the receptor as serotonin would. [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228
- Ketanserin blockade
- Pretreating with the 5-HT2A antagonist ketanserin suppresses psilocybin’s effects in humans — the central evidence that 5-HT2A activation is causal. [3] Peer-reviewed Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action doi:10.1097/00001756-199812010-00024
- Occupancy–effect relationship
- In humans, the strength of the experience scales with how much of the 5-HT2A population psilocin occupies — but only measured at perceptual doses. [4] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9
- Mixed receptor profile
- Psilocin also engages 5-HT1A and other serotonin receptors, so the net effect is not a simple function of 5-HT2A occupancy alone. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
- The microdose gap
- Sub-perceptual receptor occupancy in humans is unmeasured; the mechanism identifies the pathway without showing it is sufficiently engaged at a microdose. [6] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
Frequently asked questions
What does it mean that psilocin is a 5-HT2A agonist?
An agonist is a molecule that binds a receptor and switches it on, the way the receptor’s natural signal would. Psilocin binds the serotonin 5-HT2A receptor and activates it, mimicking part of what serotonin itself does at that site. [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 This is the interaction most closely tied to the characteristic effects of psilocybin and the other classic psychedelics, though psilocin also acts at related serotonin receptors such as 5-HT1A. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
How do we know 5-HT2A is actually the receptor responsible, and not something else?
The strongest evidence is a blocking experiment. When healthy volunteers are given ketanserin — a drug that blocks the 5-HT2A receptor — before psilocybin, the psychedelic effects are suppressed in a dose-dependent way. [3] Peer-reviewed Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action doi:10.1097/00001756-199812010-00024 If you close that one receptor and the effect largely disappears, that receptor is doing the central work. Brain-imaging studies add to this by showing that the intensity of the experience scales with how much of the 5-HT2A population is occupied. [4] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9
If a microdose uses the same receptor, why might it not produce the same kind of effect?
Because the amount of receptor activation differs enormously. The human occupancy data come from doses large enough to produce a noticeable experience, where a substantial fraction of receptors is engaged. [4] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9 A microdose is defined as too low to cross the perceptual threshold, so it occupies far fewer receptors. How much sub-perceptual activation occurs, and whether it is enough to drive any lasting change, has not been directly measured in people. [6] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
Does long-term SSRI use change how this receptor responds?
It can. Long-term SSRI exposure has been associated with adaptive changes in serotonin signalling, including changes in 5-HT2A receptor expression and sensitivity. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 Because psilocin works by activating those receptors, an adapted system may respond more weakly, which is the most likely explanation for reports of blunted effects among long-term SSRI users, though the degree varies between medications and individuals. This is a description of receptor pharmacology, not medical advice, and no one should alter prescribed medication without a clinician’s guidance.
Does activating 5-HT2A automatically cause neuroplasticity?
No. 5-HT2A activation is part of the pathway associated with psychedelic-induced plasticity, especially in preclinical research, but receptor activation on its own does not guarantee a measurable structural or behavioural change in humans. [7] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 The link from receptor to lasting change runs through downstream signalling and depends on dose, context, and individual factors, and it has been demonstrated mainly in cells and animals rather than in people taking microdoses. [6] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204